Company: IMRX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001790340-25-000135
Chunk: 561

Company: Immuneering Corp
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 2
Chunk 561
---
0.6 million decrease in spend for earlier stage programs. 

General and Administrative

The following table summarizes the components of general and administrative expenses for the periods indicated:

Nine Months Ended September 30,Change20252024$%(in thousands, except percentages)Employee-related costs$6,343 $6,300 $43 0.7 %Stock-based compensation expense2,728 2,817 (89)(3.2)%Professional fees2,343 2,051 292 14.2 %Facilities and other allocated expenses183 223 (40)(17.9)%Other1,211 993 218 22.0 %Total general and administrative$12,808 $12,384 $424 3.4 %

General and administrative expenses increased by approximately $0.4 million, or 3.4%, to approximately $12.8 million for the nine months ended September 30, 2025, as compared to approximately $12.4 million for the nine months ended September 30, 2024. The increase of approximately $0.4 million was due to an increase in professional fees incurred for accounting, auditing, legal and tax services of approximately $0.3 million, and increased other expenses of $0.2 million, primarily consisting of offering costs associated with various financing efforts during the current quarter, offset by decreased stock-based compensation expense of approximately $0.1 million and a decrease of $40 thousand in facilities and other allocated expenses.

Amortization of Intangible Asset

Amortization of intangible asset was $21,950 for the nine months ended September 30, 2025, and 2024. This amortization is related to the technology acquired for the BioArkive acquisition completed in December 2021.

Other Income (Expense)

Interest income decreased by approximately $1.0 million for the nine months ended September 30, 2025, compared to the nine months ended September 30, 2024, driven primarily by lower interest rates and a lower total cash balance.

There was no other income for the nine months ended September 30, 2025, compared to $0.4 million for the nine months ended September 30, 2024. This was primarily a result of there being no marketable securities as of September 30, 2025 and December 31, 2024, respectively.

Liquidity and Capital Resources

Sources of Liquidity

We finance our